+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the use of pemigatinib for adults with advanced or metastatic pancreatic cancer that has spread locally or to distant parts of the body. This study focuses on patients whose cancer has specific abnormal changes in the FGFR gene, which can promote cancer growth. The goal is to see if pemigatinib can block these abnormal genes to stop tumor growth and improve quality of life. Participants take pemigatinib orally once daily for 14 days in each 21-day cycle, continuing as long as the cancer does not worsen or side effects are manageable. During the study, patients undergo blood tests, CT andor MRI scans, and optical coherence tomography OCT. Additional scans like whole body bone scans and eye exams may be performed if needed. After treatment, patients are followed up 30 days later and then every 4 months for one year. Throughout the study, researchers assess tumor response using imaging and blood tests, including monitoring cell-free DNA to track response and resistance. They measure overall response rate up to 24 months and evaluate progression-free survival, disease control, overall survival, and side effects up to 12 months. Safety and tolerability are closely monitored, and patients overall health and treatment effects are regularly checked to understand the impact of pemigatinib.

Age: 18Years +All GendersPhase 2
109 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating whether providing buprenorphine treatment directly at syringe service programs SSPs helps more people with opioid use disorder OUD start and stay in treatment compared to referring them to community treatment providers. This study uses a stepped wedge design with eight SSPs across the United States, examining how low-threshold buprenorphine programs impact treatment retention, adherence, and health outcomes, while also assessing cost-effectiveness and feasibility in diverse community settings. Participants will receive either the usual care of referral to community providers or onsite, low-barrier buprenorphine treatment integrated within SSPs. The onsite program offers quick medication start, flexible scheduling, peer outreach support, and both in-person and telehealth follow-up visits approximately every four weeks for six months. The study also provides training and ongoing support to SSP staff to help implement and sustain this new treatment model. Participants will complete assessments at baseline, 1, 3, and 6 months after enrollment, including surveys on substance use, treatment engagement, overdose events, and quality of life. Urine drug screens will verify medication adherence. Researchers will monitor treatment retention at three and six months as primary outcomes, along with other health and recovery measures. The study will continue through 2028, gathering data to help improve access to life-saving opioid treatment in community settings.

Age: 18Years +All GendersPhase Not Applicable
8 locations